Abstract:The genetics of peripheral T cell lymphomas (PTCL) are poorly understood. Recently, a chromosomal translocation, t(5;9)(q33;q22), was discovered in a rare subset of PTCL with a follicular growth pattern. This translocation involved the SYK (Spleen tyrosine kinase) and ITK (Inducible T cell kinase) genes and generated an ITK-SYK fusion protein. The functional attributes of ITK-SYK are thus far uncharacterised. Here we demonstrate that ITK-SYK is an active tyrosine kinase, the expression of which resulted in ERK activation in 293T cells and transformation of NIH-3T3 cells, inducing loss of contact inhibition and formation of anchorage-independent colonies in soft agar. These observations were a direct result of the kinase activity of ITK-SYK as a kinase dead mutant was unable to induce NIH-3T3 transformation or phosphorylation of ERK. ITK-SYK is unusual amongst fusion tyrosine kinases (FTKs) as it does not contain a known oligomerisation domain but does have an N-terminal phosphatidylinositol-3,4,5-trisphosphate (PIP3)-binding pleckstrin homology (PH) domain. To investigate the importance of this domain for ITK-SYK activity we introduced a well characterised point mutation (R29C) that prevented membrane localisation. This point mutation abrogated ITK-SYK catalytic activity and inhibited its phosphorylation on its activation loop tyrosines in the kinase domain. Importantly, the R29C mutation also prevented the ability of ITK-SYK to activate the ERK signaling pathway and to transform NIH3T3 cells. However, each of these functions could be recovered by retargeting ITK-SYK-R29C back to the membrane by the addition of an N-terminal myristylation tag, thus demonstrating the importance of membrane localisation for ITK-SYK function. Furthermore, inhibition of phosphatidyl-inositol-3-kinase (PI3K) by LY294002, a well characterised PI3K inhibitor, also reduced ITK-SYK phosphorylation in a dose dependent response. Therefore, ITK-SYK activation requires PIP3 mediated membrane localisation, as seen with other PH domain containing kinases. Finally, we show that pharmacological inhibition of Syk in patients with PTCL-U carrying ITK-SYK could represent an effective treatment strategy as ITK-SYK phosphorylation was inhibited by the Syk inhibitor Piceatannol. Together these findings identify ITK-SYK as an active FTK, that is dependent upon PH domain-mediated membrane localisation for activation, signal transduction and transformation and establish it as a rational therapeutic target for t(5;9)(q33;q22)-positive PTCL. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 447.

Supplementary Table 1 from The ITK-SYK Fusion Oncogene Induces a T-Cell Lymphoproliferative Disease in Mice Mimicking Human Disease

Supplementary Figures 1-16 from the ITK-SYK Fusion Oncogene Induces a T-Cell Lymphoproliferative Disease in Mice Mimicking Human Disease

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Table 1, Figures 1-5 from TGFBI Deficiency Predisposes Mice to Spontaneous Tumor Development

Supplementary Figure 3 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Supplementary Figure 1 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Supplementary Materials and Methods and Figure Legends from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

The Histogenetic Origin of Malignant Cells Predicts Their Susceptibility towards Synthetic Lethality Utilizing the TK.007 System

Supplementary Table 1 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice

Supplementary Figure 8 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Supplementary Tables 1-2 from <i>Pten</i> Inactivation Accelerates Oncogenic <i>K-ras</i>–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Supplementary Figure 1 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells

Supplementary Figure 6 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Table 3 from <i>Pten</i> Inactivation Accelerates Oncogenic <i>K-ras</i>–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Supplementary Figure 5 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias.

Supplementary Figure 2 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Itk-Syk Requires Membrane Localisation, Via Its Pleckstrin Homology Domain, for Activation, Signal Transduction and Cellular Transformation

Supplementary Table 1 from Suppression of Tak1 Promotes Prostate Tumorigenesis